Why your health plan doesn’t cover GLP-1s, according to a top insurance exec

Employers and health plans are increasingly directing employees to cash-pay platforms for GLP-1 weight-loss medications, bypassing traditional insurance coverage. Coverage from *Managed Healthcare Executive* notes some companies are steering workers toward direct-purchase options, while *The Washington Post* cites a top insurance executive attributing the shift to cost concerns and formulary restrictions. Pharmacists, per *Pharmacy Times*, are stepping in to help patients navigate affordability and long-term access barriers, though specifics on drug tiers or employer policies remain limited.

The trend highlights a growing divide between insurer priorities and patient demand, with *The Washington Post* and *Daytona Times* framing it as a systemic issue for those relying on insurance for obesity treatments. Coverage emphasizes pharmacists’ expanding role in advocacy and logistical support, though no major policy changes or legal challenges are yet reported. Employers’ rationale—whether cost-cutting or formulary design—remains unstated in current reports.

Watch for potential legal or regulatory pushback if patients or advocacy groups challenge exclusionary practices. Cash platforms may also face scrutiny over transparency in pricing or patient outcomes. Coverage does not yet specify whether this shift applies broadly or is limited to specific plans or regions.